<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979312</url>
  </required_header>
  <id_info>
    <org_study_id>21-000284</org_study_id>
    <nct_id>NCT04979312</nct_id>
  </id_info>
  <brief_title>Glucose and Blood Pressure During Pregnancy</brief_title>
  <official_title>Predictive Role of Non-Invasive Glucose Assessment During Pregnancy: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to examine the beneficial effects of regular, non-invasive,&#xD;
      glucose (sugar) assessment on glucose (sugar) and blood pressure regulation during pregnancy&#xD;
      to help in predicting gestational diabetes and preeclampsia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label pilot trial for the LabClasp combined with standard clinical care&#xD;
      compared to standard clinical on [glucose] and blood pressure during pregnancy. Potential&#xD;
      study participants will be pre-screened using questionnaires and review of their clinical&#xD;
      records. Once the consent has been obtained, participants will undergo screening to confirm&#xD;
      eligibility. Subjects who meet all criteria will be randomized to either LC+SC or SC cohorts&#xD;
      for 24-39wks depending upon their gestational duration at enrollment. Study measures&#xD;
      including anthropometrics, surveys/questionnaires, 24hr ABPM, accelerometry, and an oral&#xD;
      glucose tolerance test (OGTT). Furthermore, the investigators will obtain repeated (annual)&#xD;
      subject information including vitals, labs, medications, and development of cardiometabolic&#xD;
      disorders for up to 10yrs in follow-up by reviewing Mayo Clinic medical records.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of gestational diabetes mellitus and preeclampsia</measure>
    <time_frame>24-39 weeks</time_frame>
    <description>measuring glucose non-invasively will prevent gestational diabetes mellitus and preeclampsia during pregnancy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Examine role of sleep as a potential mechanism in changing blood glucose in pregnancy</measure>
    <time_frame>24-39 weeks</time_frame>
    <description>measuring glucose non-invasively may aid in sleep, thereby improving blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine role of sleep as a potential mechanism in changing blood pressure in pregnancy</measure>
    <time_frame>24-39 weeks</time_frame>
    <description>measuring glucose non-invasively may aid in sleep, thereby improving blood pressure</description>
  </secondary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Gestational Diabetes</condition>
  <condition>Pre-Eclampsia</condition>
  <condition>Blood Pressure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LabClasp</intervention_name>
    <description>participants will be randomized to LabClasp + standard care or just standard care</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      10 ml blood samples will be drawn&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        pregnant women between the ages of 18-45 with risk factors for gestational diabetes and&#xD;
        preeclampsia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Age range: 18-45 years (inclusive)&#xD;
&#xD;
               -  Body mass index (BMI) ≤40kg/m2&#xD;
&#xD;
               -  &gt;1 risk factor for GDM&#xD;
&#xD;
               -  &lt;16wks gestation&#xD;
&#xD;
               -  Gender: only females will be recruited into this study&#xD;
&#xD;
               -  Target disease or condition: pregnancy&#xD;
&#xD;
               -  Individuals with treated hypertension, prehypertension, and dyslipidemia will be&#xD;
                  allowed to participate in the study&#xD;
&#xD;
               -  Ability to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Presence of chronic kidney disease (creatinine &gt;2.5mg/dL) and/or active cancer&#xD;
&#xD;
               -  Smoking&#xD;
&#xD;
               -  Multiple pregnancies&#xD;
&#xD;
               -  Congenital abnormalities&#xD;
&#xD;
               -  Use of chronic medications which influence blood [glucose] or [insulin]&#xD;
&#xD;
               -  Subsequent diagnosis of GDM&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>must be pregnant</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virend Somers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monica L Olson, MBA</last_name>
    <phone>507-255-2649</phone>
    <email>olson.monica2@mayo.edu</email>
  </overall_contact>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 14, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Virend Somers, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

